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Acute dysphonia is a frequent condition in clinical practice. Its treatment, especially in adults, is 
not well established in the literature. Steroids are the most recommended drug treatment. However, 
the existing studies are not enough to establish superiority among the different steroids and the best 
route of administration.
Objective: This prospective clinical study aimed at comparing the effect of inhaling steroids as a 
dry powder with the effect of oral steroids to treat acute dysphonia.
Method: We assessed 32 adult patients, broken down into two groups of 16 patients in each one of 
the treatments, before and seven days after the use of the medication. The patients were submitted 
to videolaryngoscopy and perceptive and acoustic voice assessment.
Result: Oral and inhalation treatment significantly reduced hyperemia and edema, and improved 
the muco-ondulatory movement; nonetheless, edema reduction was statistically more significant 
(p = 0.012) in the patients treated with the inhalation form of the drug. However, comparing the 
values of the auditory perceptive analysis and the acoustic measures after treatment between the 
groups was not statistically significant.
Conclusion: There was a significant improvement in the acute laryngitis concerning the assessments 
carried out in all the patients assessed, concerning the two treatments. The inhalation steroid treatment 
was significantly more effective in reducing the edema.
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INTRODUCTION
Acute dysphonia impacts verbal communication and 
it may lead to numerous types and levels of limitations 
which have repercussions both in the individual’s social as 
well as professional lives. In such a case, it is increasingly 
more frequent in clinical practice to have patients who 
seek medical care, eager for a rapid and effective inter-
vention, which enables voice normalization and return to 
their activities as soon as possible.
Acute dysphonia may stem from various factors, 
such as: inflammatory processes, trauma, laryngeal 
paralysis, psychological factors, and others. Laryngitis, 
inflammation of laryngeal tissues, basically characterized 
by edema and/or hyperemia, is the most frequent finding 
in the clinical exam of these patients1-3. In the acute and 
subacute forms of the disease, onset is usually sudden and 
the disease lasts for less than three weeks4.
Vocal rest is paramount in the treatment of acute 
dysphonia by laryngitis2; however, for most of the patients 
who came for medical care it is not possible to do it, other 
treatments are needed.
Steroid treatment is described as fundamental in 
the treatment of acute laryngitis, especially when there is 
breathing compromise in children and voice involvement 
in adults5-9. The goal is to reduce inflammation, relieve the 
pain and reestablish mucosal physiology. Notwithstanding, 
existing studies are not enough to establish which steroids 
are better and which are the best means of administration.
Oral steroids have a powerful anti-inflammatory 
effect and their indication in inflammatory diseases and 
laryngeal edema is well know5-8,10. When used for short 
periods of time (up to two weeks), they have a very low 
likelihood of causing side effects. Oral steroids are as 
effective as the injectable ones, which speaks against the 
use of injectable steroids when the oral administration is 
possible11.
Today, topical steroids are largely used as the 
treatment of choice for inflammatory processes of the 
airways, such as rhinitis and asthma. They have a powerful 
anti-inflammatory action and in reducing edemas. Since 
they act directly on the inflammation site, they can be used 
in lower doses. In shorter treatment courses, they have 
fewer side effects and a better safety profile than systemic 
steroids12,13. They are indicated to be used in laryngeal 
disorders, such as in the treatment of children with croup 
and laryngotracheitis, and in laryngeal edema - in cases of 
post-endotracheal laryngeal intubation edema. However, 
here are no reports of its use in acute laryngitis in adults.
Some studies have described cases of dysphonia 
and laryngeal lesions in adult patients under chronic use 
of steroids and other inhalation medication to treat asthma, 
as well as laryngeal irritation, cough and oropharyngeal 
candidiasis14-20. The lesions described are associated with 
numerous factors, such as medication dose, duration of 
use, type of inhaler and propellant and other drugs present 
in the medication, cough, gastroesophageal reflux, and/or 
associated smoking and disease, or degree of inflammatory 
process in the airway17. In all these studies, the patients 
were under use of the inhalation medication for at least 
two weeks, and the dysphonia and lesions were reversible 
after interrupting the medication.
Based on the side effects, some authors do not 
recommend the use of inhalation steroids in people who 
make professional use of their voices2,19. This may justi-
fy the fact that in the literature there is only one paper 
showing the effectiveness of inhalation steroids in acute 
laryngitis20.
This lack of studies published, coupled to the de-
mand for cases of adult patients with dysphonia associated 
with acute laryngitis, to the repercussion of the acute loss 
of voice in one’s social and professional lives and the 
need for standardization and normalizing of the existing 
treatments, motivated the development of this study.
This study aimed at assessing and comparing the 
effects of inhalation steroids (inhalation fluticasone) as a 
dry powder, with the effects of oral steroids (prednisone) in 
the treatment of dysphonia associated with acute laryngitis.
METHOD
This methodology was based on the protocol pro-
posed by Dejonckere et al.20 for the functional assessment 
of voices with disorders and their treatment, and it was 
approved by the Ethics Committee, project #501/07.
Between January of 2007 and September of 2008 we 
selected 32 adult patients with acute dysphonia caused by 
laryngitis, seen in a private clinic - specialized in profes-
sional use of the voice. We took off the study: smokers, 
people with mental disorders, those with psychological 
and motor problems; those with laryngeal paralysis or 
structural disorders, or those with a past of laryngeal 
surgery; patients under use of anti-inflammatory medi-
cation or drugs to treat gastric reflux. Those individuals 
with hypersensitivity to fluticasone or prednisolone, or 
contraindication concerning their use were taken off, as 
well as those with indications for using other drugs, such 
as antibiotics, anti-coughing medication, antipyretic or ex-
pectorants, to treat laryngitis. We took off the study those 
patients with vocal fold hematoma, because vocal rest in 
these cases would be mandatory and vocal rest was not a 
specific recommendation given to these patients.
The patients were randomly broken down into 
two groups; the first group received 50 mcg of inhalation 
fluticasone, twice-a-day, and the second group received 
20 mg of oral prednisolone, twice-a-day, both for 7 days. 
No patient was instructed to perform vocal rest. All the 
patients maintained their vocal activities.
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All the patients were assessed by videolaryngostro-
boscopy, perceptive analysis (GRBAS) and voice acoustics 
on the first and seventh (last) day of treatment. At the end 
of treatment (7th day), all of them were asked to answer 
a questionnaire.
The inhaled steroid chosen was fluticasone, since 
it was described as the most powerful inhaled steroid, 
the one remaining the longer on the mucosa and the one 
with the least systemic absorbing13,21,22. Administration of 
the inhaled dry powder, for it is the one with the least 
likelihood of causing larynx damage22,23 and the dose of 100 
mcg/day, for being the lowest effective dose and without 
reports of local or systemic side effects with this dose in 
a short-duration treatment.
Prednisolone was chosen because it is one of the 
most utilized systemic steroids, it has an intermediate 
duration half-life and causes less side effects12. The 40 mg/
day dose was the mean value of the doses recommended 
in other studies2,3,6-8.
Videolaryngostroboscopy assessment
Videolaryngostroboscopy, with a JC Biocam laryn-
goscope was always carried out by the same otorhinola-
ryngologist, on the first and 7th day.
These tests were saved using a Philips DVD 
recorder, for recording and later analysis of the following 
information: presence or absence of vocal fold hyperemia, 
presence or absence of vocal fold edema and vocal fold 
muco-undulatory movement (MOM): normal or changed. 
Any alteration in the regularity and/or symmetry of the 
MOM was considered.
Vocal assessment
After doing the videolaryngostroboscopy exam, a 
speech and hearing therapist recorded the voice.
The voice was recorded in a silence room, with 
noise levels below 50 db, by means of a Shure SM 10A, 
condensed unidirectional microphone, positioned at 45º 
and at 5 cm away from the user’s mouth. It was then con-
nected to an Eurorack UB502 sound board, directly atta-
ched to a Pentium 5 Toshiba laptop with a Sound Blaster 
32 soundboard from creative labs. The patient was asked 
to perform the following phonation activities:
•	 Utter the vowel [a] three times, as long as 
possible (sustained in one single exhalation), 
in a habitual tone to measure the maximum 
phonation time and for a perceptive assessment 
utilizing the GRBAS scale.
•	 Utter the sustained vowel [e] for acoustic 
analysis purposes.
For such acoustic analysis, aiming at doing a quan-
titative analysis of the sound, we utilized the DR Speech 
software, version 3.1 and measured the mean values of the 
fundamental frequency (Fo), jitter, shimmer, neutralized 
noise energy (NNE) and the harmonic noise ratio (HNR), 
utilizing a middle stretch of the sustained vowel [e] utte-
red - such vowel is the basis of the DR Speech program.
Questionnaire
On the 7th day of treatment, the patients from both 
groups were asked to answer a written questionnaire, 
reporting whether or not there had been any voice 
improvements with the treatment (yes or no), which 
day the voice improved (1st through the 7th) and report 
treatment-related side effects.
Data analysis
The videolaryngoscopy recordings from each indi-
vidual were shown to two otolaryngologists with expe-
rience in laryngology and in laryngeal exams (blinded as 
to which group the exam came from), the examiners were 
also blinded as to pre and post-treatment; and patient and 
exam dates were randomized.
The perceptive analysis of the vocal samples was 
carried out by three speech and hearing therapists - voice 
specialists, blinded as to and pre and post-treatment; and 
patient and exam date of the sustained [a] vowel were 
randomized. We utilized the GRBAS scale.
In order to establish the maximum phonation time, 
we utilized the mean value, in seconds, of the three sam-
ples of the vowel [a] as prolonged as possible (sustained 
in one single exhaling), in the patient’s regular tone.
For acoustic analysis purposes, we utilized the 
mean values from the measures made by the DR Speech 
software, version 3.1, from the three samples of the mean 
utterance of the sustained vowel [e], before and after 
employing the treatments.
The results from the above analysis and the questio-
nnaires were plotted on a table and submitted to statistical 
analysis.
RESULTS
The statistical comparison of the variables: gender, 
age, profession, videolaryngostroboscopy data, and the 
auditory-perceptive assessments by the GRBAS scale and 
voice acoustics from the two groups before treatment, 
showed that the groups were similar in the beginning.
Videolaryngoscopy showed a significant reduc-
tion in hyperemia, edema and improvement in the 
muco-undulatory movement of the vocal folds after treat-
ment. Edema reduction was statistically more significant in 
those patients treated with inhaled fluticasone (Table 1).
In the perceptive assessment of the voice, both 
groups showed a significant improvement in voice quality, 
roughness and breathiness. Tension did not vary signi-
ficantly between the two groups, and asthenia was not 
detected in any of the analyzed cases (Table 1).
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Table 1. Summary of the videolaryngostroboscopy and perceptive assessment (GRBAS) data before and after treatment with 
prednisolone and fluticasone and post-treatment comparison between the groups.
Variable
Ratio difference before x after Comparison of the post-treatment assessment between the groups
Prednisolone Fluticasone p-value
Hyperemia -62.5 -62.5 1.000
Edema -37.5 -81.3 0.012
Altered muco-undulatory movement -50.0 -62.5 0.476
Full voice assessment 62.5 37.5 0.780
Roughness 37.5 31.3 1.000
Breathiness 56.3 43.8 O.780
Stress 18.8 12.5 1.000
The negative sign in the first three variables indicates a reduction in the trait.
Table 2. Comparison of the acoustic assessment data before x after the p value in the treatments with prednisolone and fluticasone 
and between the groups after treatment.
Variable
Comparison between the values before x after (p-value) Comparison between the groups 
after treatment (p-value)Prednisolone Fluticasone
Maximum phonation time (s) 1.000 0.164 0.876
Fundamental frequency (Hertz) 0.832 0.469 0.692
Jitter (%) 0.362 0.036 0.356
Shimmer (%) 0.044 0.205 0.083
Harmonic noise ratio: HNR (db) 0.438 0.121 0.089
Neutralized noise energy: NNE (db) 0.001 < 0.001 0.448
Figure 1. Day of improvement with the treatment reported by the patient.
The computerized acoustic analysis found a signifi-
cant improvement in shimmer and NNE in those patients 
treated with oral prednisolone and in the jitter and NNE 
in those patients treated with inhaled fluticasone. The 
comparison of the post-treatment measures in both groups 
was not statistically significant (Table 2).
In the questionnaires, all the patients reported 
improvements by the 5th day of treatment. The logrank 
statistical analysis generated a p value = 0.627 indicating 
that there was no difference between the time to impro-
ve for patients using prednisolone and those who used 
fluticasone (Figure 1).
Of those patients who used prednisolone, four 
reported side effects (stomach pain and nausea) and one 
of the patients who used fluticasone reported an urge to 
cough upon drug administration.
DISCUSSION
Acute dysphonia which limits verbal communi-
cation and prevents normal day-to-day activities is a 
common reason to seek medical care, especially in those 
patients who make a professional use of their voices. 
Before entering in the discussion part, we have to stress 
that in this paper we had two groups using the medica-
tion (inhalation and oral) and no control group without 
medication. This would enable us to answer how much 
of the development of these cases would be different in 
non-treated patients. Since this is a sample in which most 
individuals make professional use of their voices, the use 
of a placebo group brought about an important limitation 
in individual compliance towards participation. Patients in 
need of fast improvement did not feel comfortable with 
the possibility of being treated with a placebo. Having 
this difficulty, we decided to study these two treatment 
modalities, comparing the efficacy of the most-frequently 
mentioned treatment modalities in the literature.
Signs of acute inflammatory process (laryngeal hype-
remia and edema, and alterations to the muco-undulatory 
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movements of the vocal folds) were present in all dys-
phonic patients assessed by videolaryngostroboscopy in 
this study, before and after treatment. Seven days after 
the treatment with inhaled steroids (fluticasone) and oral 
steroids (prednisolone), there was an improvement in 
these signs in all the patients (100%), from both groups. 
However, edema reduction was greater in the group tre-
ated with the inhaled steroid.
The efficacy of oral steroids in the treatment of 
dysphonia caused by acute laryngitis is known in adults 
and has been described by some authors:
Mishra et al.1 mentioned oral and intramuscular ste-
roids as the first-line treatment for singers with dysphonia 
caused by laryngitis, although they reported not finding 
any careful study on their efficacy in adults. These authors 
found only treatment studies based on subjective impro-
vements and positive effects in pediatric patients, which 
we also found in our review of the literature.
Spiegel et al.6 suggested systemic steroids as power-
ful anti-inflammatory agents to treat dysphonia associated 
with acute laryngitis. Nonetheless, they reported that many 
otorhinolaryngologists use low doses (they mentioned 
10mg of methylprednisolone), and that higher doses used 
for longer periods of time are more effective.
Sataloff et al.7 and Watts et al.8 reported cases of 
individuals making professional use of their voices, with 
acute laryngitis-related dysphonia, who needed to make 
an important speech, were successfully treated with oral 
steroids.
Klein et al.2 suggested the use of injectable or oral 
steroids in the treatment of laryngeal edema and acute 
vocal disorders.
Klassen10 and Pedersen et al.11 described the inha-
lation steroid as a better option in the anti-inflammatory 
drug-treatment for the airways, because of its high power 
as a topical agent and they stated that this is the ideal treat-
ment for it produces a faster reduction in the inflammatory 
process, vascular permeability and mucosa edema. No 
study compared the two forms of treatment. In the litera-
ture, the studies are limited to case reports and citations, 
but without comparing the different forms.
The improvement in vocal quality seen in the global 
voice assessment parameters, roughness and breathiness, 
in both groups, after treatment was expected as a conse-
quence to the improvement in the inflammatory process 
seen upon the videolaryngostroboscopy assessments. The 
stress parameter improved after treatment in both groups, 
but such improvement was not statistically significant in 
any of them. This result may be explained by the acute 
inflammatory process in the larynx. The stress is associated 
with the vocal effort caused by an increase in glottal adduc-
tion (adductor hyperfunction) which, in cases of acute 
laryngitis, may be limited because of discomfort and pain.
What was expected from the acoustic measures in 
the patients studied after a reduction in the inflammatory 
process was an increase in the mean values of the Fo, 
TMF and HNR, and a reduction in Jitter, Shimmer and 
NNE values. The expected happened in all the measures, 
in both treatments, when we analyzed the mean values. 
However, the changes were statistically significant only for 
the following variables: NNE in both groups, shimmer in 
the group with prednisolone and jitter in the fluticasone 
group.
The lack of total remission of the inflammation 
after treatment in some patients and a possible influence 
of a recent inflammatory process could justify the 
non-significant differences. Moreover, it is known that 
the acoustic assessment reliability depends on the quality 
of the recordings24. Patients with acute laryngitis have a 
major alteration in the quality of their voices associated 
with phonation irregularities, which makes it difficult 
to record their voices and causes these measures to be 
more prone to errors. In our study, the NNE detected a 
significant improvement after treatment in both groups 
assessed. NNE measures the sound wave noise, which 
is highly correlated with the auditory perception of dys-
phonia and roughness. Since it has the noise component 
as a basis, it is mentioned by Dejonckere20 and Pinho & 
Camargo25 as one of the most sensitive acoustic measures 
in the assessment of dysphonic voices.
Only a few authors have assessed acoustic measures 
in patients with laryngitis.
Plante et al.26 assessed the effectiveness of some 
objective acoustic analysis parameters during and after 
infectious laryngitis in four patients, and compared it with a 
control group having four healthy patients. The parameters 
investigated were: jitter, GNE (glottal to noise excitation) 
and the normalized error prediction (NEP). In this study, 
we used different programs and showed that it is possible 
to separate individuals with hoarseness from individuals 
with normal voice or after laryngitis recovery, using these 
three parameters. These authors discussed the variability 
of the parameters found among individuals of the same 
group and showed that this comparison is rather difficult. 
Each individual has his/her own phonation apparatus and 
physiology, and this introduces signal variations. Monito-
ring voice quality in the same individual is easier and more 
reliable, since it is the same phonation apparatus - and we 
also noticed this in our study. The individual comparative 
analyses showed significant statistical variations in our 
study before and after the two treatments (shimmer and 
NNE for prednisolone and Jitter and NNE for fluticasone), 
but these differences disappeared when we statistically 
analyzed the final measures in the two groups.
Ng et al.27 investigated the effect of acute laryngitis 
on the perceptive and acoustic aerodynamic measures 
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in 11 patients with acute laryngitis before and after 7 
to 10 days and compared with normal individuals. The 
fundamental frequency was reduced in the patients with 
laryngitis, suggesting an increase in the mass of the vocal 
folds during the course of laryngitis. The aerodynamic 
values were different in the cases of laryngitis, suggesting 
laryngeal hypofunction. The perceptive data showed the 
hoarseness of the patients with laryngitis - which was also 
observed in this study.
Watts et al.13 carried out a study with a patient with 
acute laryngitis, treated for six days with oral steroids, 
with the goal of assessing the effectiveness of treatment 
considering the acoustic measures on days 1, 3, 5 and 
7. Their results showed a significant increase in the fun-
damental frequency, reduction in jitter, shimmer and in 
amplitude variability. These measures were not always 
linear, showing some oscillations which were contrary to 
what was expected in a few days - and we also found this 
in some of our patients. These oscillations happened, as 
per described above, because of difficulties to record the 
voice and the phonation instability inherent to patients 
with acute laryngitis.
Upon questionnaire assessment, all the patients 
studied in both groups reported improvements after 
treatment, correlated with what was observed in the as-
sessments made by videolaryngostroboscopy and vocal 
assessment. They all reported improvements by the 5th 
day of treatment, with a peak improvement on the 3rd 
day, and there was no statistical difference in when the 
improvement happened between the patients who used 
the inhalation steroid (fluticasone) and oral (prednisolone). 
This data makes us rethink treatment duration. Would five 
days be enough?
Spiegel et al.6 reported that to treat acute laryn-
gitis in adults, higher doses used for shorter periods of 
time are more effective, and they suggested 60 mg of 
prednisolone for 3 to 6 days. Watts et al.8 used 24 mg of 
methylprednisolone in a voice professional in the first 
day, and reduced it in 4 mg increments down to the 6th 
day; and Franco & Andrus3 reported 16 mg/day of me-
thylprednisolone, with a 4 mg reduction per day during 
7 days. The ideal dose of the oral or inhaled medication 
is still uncertain, and we still need studies comparing the 
different therapeutic doses.
In our sample, four (25%) of the 16 patients who 
used the oral steroid (prednisolone) reported side effects 
(stomach pain and nausea) and one (6.3%) of the 16 pa-
tients who used inhaled steroids reported an urge to cough 
upon drug administration. These results are in agreement 
with the reports from Roland et al.15, who stated that the 
side effects of inhaled steroids, when compared to the 
systemic ones, are considered rare and milder. Spiegel et 
al.6 and Abaza et al.17 mentioned gastric irritation as one of 
most common adverse effects associated with oral steroids. 
The concomitant use of antacids, as per recommended 
by Abaza et al.17, during treatment with oral steroids is a 
suggestion to prevent gastric effects.
In none of the patients who used the inhaled steroid 
we noticed the laryngeal alterations described for asthma-
tic patients in chronic use of inhaled steroids14-19. As per 
described by Watts13, we believe that these changes do 
not happen when low doses are used for just a few times 
a day and for a short period of time. The benefits surpass 
the potential risks, and inhaled steroids may be used with 
significant safety. The fear of adverse effects may stem from 
the lack of an effective and less risky treatment. We must 
stress that many patients, especially voice professionals, 
may have more frequent laryngitis episodes3 and a greater 
need to use steroids.
As to the inhaled steroid means of administration 
(inhaler type), we agree with Selroos et al.23 and Castro 
et al.22 who stated that the dry powder inhalers may be 
safer. They do not require propellants (which may cause 
irritation), since it is the patient’s own breathing effort that 
causes drug dispersion in the airway. The patient must be 
instructed to wash the mouth after inhaling, in order to 
avoid side effects in this region, and he/she must also be 
instructed to make a medium intensity inhaling, because 
the goal is that the medication should reach the larynx 
with little impact.
We find it interesting to mention the review made 
by Mash et al.28 which, despite assessing studies from 
adult patients with asthma, had a similar goal to ours - to 
compare inhaled steroids (of different types) with oral 
prednisolone. This review assessed 1,285 studies and 
abstracts comparing inhaled steroids up to 2,000 mcg/day 
with oral steroids (specifically oral prednisone or predni-
solone in up to 60 mg/day) in the treatment of adults with 
asthma. Only eight studies fulfilled the inclusion criteria. 
In six studies, prednisolone seemed to be as efficient as 
the inhaled steroid. In two trials, the inhaled steroid was 
more effective than prednisone. All inhaled steroid doses 
were more efficient than prednisolone in doses up to 
60 mg in alternate days. The data reported on adverse 
effects were too variable to allow any comparison. A 30% 
incidence of patients receiving prednisolone in one study 
was reported, and there were no reports of adverse effects 
involving inhaled steroids.
And finally, we stress the recommendations from 
Spiegel et al.6 and Abaza et al.17 on the need for education, 
especially for voice professionals, in order to avoid abusing 
steroids. These drugs produce excellent clinical effect, with 
relatively few side effects when used for shorter periods of 
time and in low doses for the treatment of vocal disorders 
caused by inflammatory processes, but the risks of side 
effects may increase with frequent use.
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CONCLUSION
There was a significant improvement in the acu-
te laryngitis vis-à-vis the assessments made, in all the 
patients studied, with both treatment modalities after 7 
days. Treatment with the inhaled steroids (fluticasone) 
was significantly more effective in reducing the edema 
and produced fewer side effects than the treatment with 
oral steroids in this study.
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